JP2011016849A5 - - Google Patents

Download PDF

Info

Publication number
JP2011016849A5
JP2011016849A5 JP2010236087A JP2010236087A JP2011016849A5 JP 2011016849 A5 JP2011016849 A5 JP 2011016849A5 JP 2010236087 A JP2010236087 A JP 2010236087A JP 2010236087 A JP2010236087 A JP 2010236087A JP 2011016849 A5 JP2011016849 A5 JP 2011016849A5
Authority
JP
Japan
Prior art keywords
depot preparation
crystals
preparation according
crystal
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010236087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011016849A (ja
JP5670698B2 (ja
Filing date
Publication date
Priority claimed from GBGB0216416.8A external-priority patent/GB0216416D0/en
Application filed filed Critical
Publication of JP2011016849A publication Critical patent/JP2011016849A/ja
Publication of JP2011016849A5 publication Critical patent/JP2011016849A5/ja
Application granted granted Critical
Publication of JP5670698B2 publication Critical patent/JP5670698B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2010236087A 2002-07-15 2010-10-21 イロペリドンの結晶を含有する注射用デポ製剤 Expired - Lifetime JP5670698B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0216416.8 2002-07-15
GBGB0216416.8A GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004520629A Division JP5392961B2 (ja) 2002-07-15 2003-07-14 イロペリドンの結晶を含有する注射用デポ製剤

Publications (3)

Publication Number Publication Date
JP2011016849A JP2011016849A (ja) 2011-01-27
JP2011016849A5 true JP2011016849A5 (https=) 2011-12-15
JP5670698B2 JP5670698B2 (ja) 2015-02-18

Family

ID=9940486

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004520629A Expired - Lifetime JP5392961B2 (ja) 2002-07-15 2003-07-14 イロペリドンの結晶を含有する注射用デポ製剤
JP2010236087A Expired - Lifetime JP5670698B2 (ja) 2002-07-15 2010-10-21 イロペリドンの結晶を含有する注射用デポ製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004520629A Expired - Lifetime JP5392961B2 (ja) 2002-07-15 2003-07-14 イロペリドンの結晶を含有する注射用デポ製剤

Country Status (15)

Country Link
US (5) US20050250813A1 (https=)
EP (1) EP1523335B1 (https=)
JP (2) JP5392961B2 (https=)
AT (1) ATE348635T1 (https=)
AU (1) AU2003281154B2 (https=)
CA (1) CA2492467C (https=)
CY (1) CY1106305T1 (https=)
DE (1) DE60310564T2 (https=)
DK (1) DK1523335T3 (https=)
ES (1) ES2279153T3 (https=)
GB (1) GB0216416D0 (https=)
NZ (1) NZ537598A (https=)
PT (1) PT1523335E (https=)
WO (1) WO2004006886A2 (https=)
ZA (1) ZA200410323B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436439T3 (es) 2001-10-30 2014-01-02 Novartis Ag Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
MY152789A (en) 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
EP2198048A2 (en) 2007-09-10 2010-06-23 Vanda Pharmaceuticals Inc. Prediction of qt prolongation based on snp genotype
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
SI2222300T1 (sl) 2007-12-13 2014-11-28 Vanda Pharmaceuticals Inc. Postopek in sestavek za zdravljenje stanja, posredovanega z receptorjem serotonina
WO2010031497A1 (en) * 2008-09-19 2010-03-25 Miklos Vertessy New process for the preparation of iloperidone
CN101822673B (zh) * 2009-03-04 2013-09-18 北京德众万全药物技术开发有限公司 一种含有伊潘立酮的固体药物组合物
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2479176B1 (en) * 2009-09-19 2014-09-17 Zhejiang Huahai Pharmaceutical Co., Ltd. Method for preparation of iloperidone and crystallization method thereof
CN102030744B (zh) * 2009-09-30 2013-04-17 天津药物研究院 伊潘立酮晶体、其制备方法及药物组合物
WO2011055188A1 (en) * 2009-11-05 2011-05-12 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of iloperidone
MX2012007365A (es) * 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
CN102108081A (zh) * 2009-12-25 2011-06-29 重庆医药工业研究院有限责任公司 伊潘立酮的新晶型及其制备方法
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
PH12012501906A1 (en) 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
CN101822674B (zh) * 2010-05-27 2015-03-11 北京德众万全医药科技有限公司 一种伊潘立酮药物组合物及其制备方法
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
WO2012090138A1 (en) 2010-12-27 2012-07-05 Ranbaxy Laboratories Limited Processes for the preparation of iloperidone
CN102680636A (zh) * 2011-03-11 2012-09-19 天津药物研究院 一种伊潘立酮原料药及其中间体的质量控制方法
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112951A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
CN102659771B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
CN102633786B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
BR112014028446A2 (pt) 2012-05-18 2017-10-24 Vanda Pharmaceuticals Inc composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
WO2016134049A1 (en) 2015-02-17 2016-08-25 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
CN106831741B (zh) * 2016-12-28 2019-08-23 北京医药集团有限责任公司 一种伊潘立酮超细粉体的制备方法
US10935106B2 (en) * 2018-06-14 2021-03-02 Serapid, Inc. Block chain with monolithic links
CN113164382A (zh) * 2018-12-04 2021-07-23 万达制药公司 伊潘立酮的贮库施用
US20200171018A1 (en) * 2018-12-04 2020-06-04 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB216416A (en) 1923-09-06 1924-05-29 James Baker And Sons Ltd Improvements in boots and shoes
IT1093097B (it) * 1976-10-28 1985-07-19 Hoechst France Acidi n-carbetossi(alfa-amminofenilacetici)otticamente attivi relativo procedimento di produzione e loro impiego per la produzione di acidi alfa-ammino-fenilacetici otticamente attivi corrispondenti
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3345355A1 (de) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
DE3511587A1 (de) 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ES2076253T3 (es) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
WO1991018927A1 (en) * 1990-06-04 1991-12-12 Schering Corporation Method for preparing interferon alpha-2 crystals
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
CA2148823C (en) 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5902882A (en) * 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
PL337027A1 (en) * 1997-05-26 2000-07-31 Akzo Nobel Nv Salts of aromatic sulphonic acids
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
PL348107A1 (en) 1998-10-16 2002-05-06 Janssen Pharmaceutica Nv Therapy for improving cognition
US6509310B1 (en) 2000-06-01 2003-01-21 Huish Detergents, Inc. Compositions containing α-sulfofatty acid esters and method of making the same
AU2001263775A1 (en) 2000-06-02 2001-12-11 Novo-Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
DK1425272T3 (da) * 2001-08-31 2011-11-21 Novartis Ag Optiske isomerer af en iloperidon-metabolit
ES2436439T3 (es) * 2001-10-30 2014-01-02 Novartis Ag Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2011016849A5 (https=)
ES2279153T3 (es) Formulacion de depositio inyectable formada por cristales de iloperidona.
JP2017523225A5 (https=)
JP2013542247A5 (https=)
JP2010524932A5 (https=)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013508279A5 (https=)
JP2015524450A5 (https=)
JP2013542263A5 (https=)
JP2015508103A5 (https=)
JP2015529229A5 (https=)
JP2020507589A5 (https=)
JP2006510618A5 (https=)
JP2009513658A5 (https=)
JP2017531619A5 (https=)
RU2015143843A (ru) Ингибиторы гистондеацетилазы
JP2013542264A5 (https=)
JP2011516460A5 (https=)
JP2015051983A5 (https=)
JP2014520886A5 (https=)
RU2014112108A (ru) Составы с производными децитабина
JP2011516511A5 (https=)
ES2324009A1 (es) Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP2016540811A5 (https=)
JP2016508030A5 (https=)